Regen BioPharma, Inc. (RGBP)
OTCMKTS
· Delayed Price · Currency is USD
0.0550
+0.0038 (7.42%)
Apr 23, 2025, 4:00 PM EDT
Regen BioPharma Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2015 - 2019 |
| Cash & Equivalents | 0 | 0.12 | 0.05 | 0.73 | - | Upgrade
|
| Cash & Short-Term Investments | 0 | 0.12 | 0.05 | 0.73 | - | Upgrade
|
| Cash Growth | -99.41% | 136.38% | -92.96% | - | - | Upgrade
|
| Accounts Receivable | 0.09 | - | 0.25 | 0.21 | 0.1 | Upgrade
|
| Other Receivables | - | - | - | 0 | - | Upgrade
|
| Receivables | 0.09 | - | 0.25 | 0.22 | 0.1 | Upgrade
|
| Prepaid Expenses | 0.06 | 0.01 | 0.03 | 0.05 | 0 | Upgrade
|
| Total Current Assets | 0.16 | 0.13 | 0.34 | 0.99 | 0.1 | Upgrade
|
| Long-Term Investments | 0.02 | 0.22 | 0.22 | 0.22 | 0.02 | Upgrade
|
| Total Assets | 0.18 | 0.35 | 0.56 | 1.21 | 0.12 | Upgrade
|
| Accounts Payable | 0.03 | 0.03 | 0.03 | 0.09 | 0.11 | Upgrade
|
| Accrued Expenses | 1.66 | 1.64 | 2 | 2.27 | 2.09 | Upgrade
|
| Short-Term Debt | 0.29 | 0.1 | 0 | 1.43 | 0.06 | Upgrade
|
| Current Portion of Long-Term Debt | 0.5 | 0.51 | 1.27 | 2.15 | 2.54 | Upgrade
|
| Current Unearned Revenue | 1.47 | 1.61 | 1.72 | 1.84 | - | Upgrade
|
| Other Current Liabilities | 1.42 | 1.42 | 3.57 | 6.91 | 2.65 | Upgrade
|
| Total Current Liabilities | 5.37 | 5.31 | 8.6 | 14.7 | 7.46 | Upgrade
|
| Long-Term Debt | - | 0.15 | - | - | - | Upgrade
|
| Total Liabilities | 5.37 | 5.46 | 8.6 | 14.7 | 7.46 | Upgrade
|
| Common Stock | 0 | 0 | 0.5 | 0.44 | 0.16 | Upgrade
|
| Additional Paid-In Capital | 15.42 | 14.64 | 12.32 | 9.38 | 9.05 | Upgrade
|
| Retained Earnings | -20.62 | -19.75 | -20.91 | -23.35 | -16.58 | Upgrade
|
| Comprehensive Income & Other | - | -0 | - | - | - | Upgrade
|
| Total Common Equity | -5.2 | -5.1 | -8.08 | -13.53 | -7.38 | Upgrade
|
| Shareholders' Equity | -5.19 | -5.1 | -8.04 | -13.49 | -7.33 | Upgrade
|
| Total Liabilities & Equity | 0.18 | 0.35 | 0.56 | 1.21 | 0.12 | Upgrade
|
| Total Debt | 0.79 | 0.76 | 1.27 | 3.58 | 2.6 | Upgrade
|
| Net Cash (Debt) | -0.79 | -0.64 | -1.22 | -2.86 | -2.6 | Upgrade
|
| Net Cash Per Share | -0.10 | -0.09 | -0.19 | -0.71 | -1.39 | Upgrade
|
| Filing Date Shares Outstanding | 10.52 | 7.12 | 6.71 | 6.09 | 5 | Upgrade
|
| Total Common Shares Outstanding | 10.52 | 7.01 | 6.71 | 5.8 | 2.14 | Upgrade
|
| Working Capital | -5.21 | -5.18 | -8.26 | -13.7 | -7.35 | Upgrade
|
| Book Value Per Share | -0.49 | -0.73 | -1.21 | -2.33 | -3.45 | Upgrade
|
| Tangible Book Value | -5.2 | -5.1 | -8.08 | -13.53 | -7.38 | Upgrade
|
| Tangible Book Value Per Share | -0.49 | -0.73 | -1.21 | -2.33 | -3.45 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.